Overview:

Multimodal imaging has evolved as a key technology in preclinical research, combining morphological, functional, and molecular imaging. Near-infrared optical imaging enables precise and dynamic biodistribution studies, whereas the use of luciferases as reporter genes is successfully applied both in transgenic reporter animals and in cancer models.

To overcome the limitations of 2-D optical imaging, we apply optical tomographic imaging combined with contrast agent enhanced computed tomography and MRI. Applying these technologies, we could follow the biodistribution of nucleic acids and nanoparticles labeled with the near infrared-emitting fluorophores. Combing bioluminescence imaging with CT and/or MRI, we could demonstrate efficient transfection of tumor lesions and therapeutic response of individual tumor lesions after combined chemo and immunotherapy. Currently, we are developing a multimodal imaging approach by fusing MRI with tomographic optical imaging.

About the speaker:

Dr. Manfred Ogris, PhD .

Professor, University of Vienna 

Dr. Ogris is a professor of Pharmaceutical Sciences at the University of Vienna. He studied Biotechnology and graduated from the University of Live Sciences in Vienna. After a Postdoctoral stay at the CRC Institute of Cancer Research, University of Birmingham/UK, he joined the Ludwig-Maximilians-University Munich as a workgroup leader with a research focus on cancer gene therapy.

In 2013, he was appointed as a full professor at the University Vienna, where he founded and heads the MMCT lab. The lab has a strong focus on the development of macromolecular formulations for targeted drug and nucleic acid-based therapies and uses multimodal imaging to study their pharmacokinetics and pharmacodynamics.